Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Hepatol. Nov 27, 2020; 12(11): 1076-1088
Published online Nov 27, 2020. doi: 10.4254/wjh.v12.i11.1076
Figure 5
Figure 5 Rate of patients with low hepatitis B surface antigen levels (Hepatitis B surface antigen < 100 IU/mL and 100-1000 IU/mL) according to treatment group. A: NA group; B: Peg-IFN-NA group. NS: Not significant; NA: Nucleos(t)ids analogue; Peg-IFN: Pegylated interferon.